BICYCLE THERAPEUTICS TO PRESENT PRECLINICAL DATA ON LEAD MOLECULE BT1718 AT THE AACR-NCI-EORTC INTERNATIONAL CANCER CONFERENCE

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that the company will present data describing the mechanism of action of BT1718, Bicycle’s lead molecule, which is being developed to target cancers of high unmet need including triple negative breast cancer and non small cell lung cancer. The data will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Philadelphia, Pennsylvania from October 26 – 30, 2017.

Read More